We Elevate the Fundamentals.
M6P Therapeutics, or M6PT, is a life sciences company whose mission is clear and simple: to translate the M6PT innovation into more effective next generation therapies for individuals affected by lysosomal storage disorders (LSDs) – to relieve suffering, to restore health, to increase hope, and to improve lives.
M6PT has the team to do it. We are skilled and experienced in the discovery, non-clinical, clinical, and commercial development of drugs that treat rare diseases.
M6PT has the tools to do it. Our S1S3 co-expression platform technology enables consistently well phosphorylated next generation lysosomal enzymes with mannose 6-phosphate (M6P) for developing LSD treatments.
M6PT has the drive to do it. As stewards of a breakthrough technology, we push forward to develop and deliver next generation treatments to individuals affected, caregivers, healthcare providers, physicians, and global health systems.
Private, Venture Backed
St. Louis, Mo
M6PT: Building a Biotech Company Efficiently
S1S3 Co-Expression Platform Creation:
Series A Financing Round:
2021 Preclinical Data:
- WORLDSymposium™ 2021 Researchers presented promising preclinical data in both Gaucher disease and mucolipidosis type II (ML II). Read the full release here
- American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting. 2021: M6PT presented preclinical proof-of-concept data for M002, its gene therapy candidate for ML II. Read the full release
- 16th Annual International Symposium of MPS and Related Diseases (MPS 2021): M6PT presented pre-clinical proof-of-concept data on M041, an enzyme replacement therapy in development, for the Treatment of Sanfilippo B Syndrome. Read the full release
- 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs): M6PT presented preclinical data on Batten disease. Read the full release